5 SIMPLE TECHNIQUES FOR TRASTUZUMAB DERUXTECAN COPYRIGHT

Just about the most less than-investigated “driving forces” associated with trastuzumab resistance is PTEN. Nagata et al. (2004) noted which the loss of PTEN was observed in 36% of HER2-optimistic Main breast tumor specimens from individuals with stage IV illness. Also, Additionally they showed that patients with PTEN-deficient tumors had remar